Skip to main content
International Journal of Molecular Sciences logoLink to International Journal of Molecular Sciences
. 2026 Oct 27;27(21):9586. doi: 10.3390/ijms27219586

Quantitative Bioluminescent Imaging of AHR Activity Using a Thermostable Variant of the Fungal Luciferase nnLuz

Hannah J Gleneadie 1,*, Nicolas Veland 1, Nadezhda M Markina 2,3, Alessandro Sardini 4, Anastasia A Fadeeva 3, Zoe Webster 5, Feng Gao 6, Matthias Merkenschlager 7, Amanda G Fisher 1,8, Karen S Sarkisyan 6,9,*
Editor: Suzanne F Scarlata
PMCID: PMC13762613  PMID: 43027834

Abstract

Bioluminescent reporters are important tools in biomedical research. Luciferase enzymes, expressed as part of transgenes or inserted into endogenous genomes, can be used to visualise molecular events with minimally invasive experiments. However, the reaction requires addition of the substrate, luciferin. Organisms with self-sustained luminescence that both express the luciferase and produce the luciferin would allow continuous, convenient and affordable acquisition of physiological information. The Neonothopanus nambi fungal bioluminescence pathway has been harnessed in this way to produce autoluminescent plants. However, progress into mammalian models has been hindered by temperature sensitivity of the wild-type fungal luciferase (nnLuz). We tested the efficacy of a thermostable variant of nnLuz (nnLuz_v3) in vivo at physiologically relevant levels, by generating a reporter of endogenous Cyp1a1 expression as a measure of aryl hydrocarbon receptor (AHR) activation. Previously published Cyp1a1-Fluc mice allowed a comparison between the novel luciferase nnLuz_v3 and the established firefly luciferase (Fluc). In Cyp1a1-nnLuz_v3 mice, the bioluminescence signal was sufficiently stable to enable well-resolved luminescence images to be captured on standard in vivo imaging equipment and consumer-grade cameras. These results derisk the use of nnLuz_v3 as an in vivo molecular reporter whilst providing a novel tool for AHR drug discovery and research.

Keywords: bioluminescence, fungal luciferase, aryl hydrocarbon receptor (AHR), Cyp1a1, endogenous reporter, autoluminescence

1. Introduction

The use of reporter genes to visualise molecular events is an important tool in biological research, with light being the most commonly used modality. Plants, animals and cellular systems are modified to express fluorescent or luminescent reporters upon activation of a regulatory region or a gene of interest. In animals, fluorescence-based reporters become largely unusable in vivo due to autofluorescence of tissues and poor delivery of excitation light. In contrast, bioluminescent reporters possess the advantage of virtually no background signal [1,2]. The enzyme luciferase catalyses the luminescence reaction, oxygenating the substate luciferin and producing light as a biproduct. Hundreds of examples of luminescence have been identified throughout the natural world, with a number of original and modified luciferase/luciferin pairs used regularly in biomedical research [3,4]. However, these rely on the exogenous addition of the luciferin substrate, making imaging invasive, discontinuous, expensive and subject to uneven tissue distribution. Therefore, for a number of in vivo applications, the ultimate light-based molecular reporter could be self-sustained luminescence, where both the luminescence substrate and the luciferase enzyme are produced in a single organism.

Only two luciferin biosynthesis pathways have been fully deciphered: the bacterial (lux) pathway [5] and the fungal (luz) pathway [6]. Constitutive expression of the complete bacterial pathway has been used to generate autoluminescent mice [7], which have been further adapted for cellular-scale autoluminescent imaging of neurons [8]. However, whilst the expression of the complete fungal bioluminescence pathway can generate autoluminescent plants and fungi [9,10,11], it has not yet been used in warm-blooded animals. The Neonothopanus nambi bioluminescence pathway is a short cycle within fungal phenylpropanoid metabolism, catalysed by four enzymes, with the light-emitting reaction performed by the luciferase, nnLuz (Figure 1a) [11]. Wild-type nnLuz displays poor activity at temperatures above 30 °C, limiting its use in mammalian cells [6]. To address this, we previously showed that variants carrying three substitutions, T99P, T192S and A199P (nnLuz_v3), outperformed wild-type controls when transiently expressed in mammalian cells at 37 °C [10]. However, whether this improvement would translate into transgenic animal models was unclear. Here, we tested the efficacy of this thermostable nnLuz variant in mice at physiologically relevant expression levels using aryl hydrocarbon receptor (AHR) activation as a model.

Figure 1.

Figure 1

Generation and characterisation of endogenous bioluminescent reporter of AHR activation using fungal luciferase nnluz_v3. (a) Schematic outlining the fungal luciferin pathway. Hispidin synthase (HispS) converts caffeic acid into hispidin, which is then hydroxylated by H3H into 3-hydroxyhispidin (fungal luciferin). The luciferase enzyme (Luz) converts luciferin into oxyluciferin and produces light [6]. (b) Schematic outlining the engineered Cyp1a1 locus in Cyp1a1-nnLuz_v3 mice and mouse embryonic stem cells (mESCs). nnLuz_v3 and iRFP670 were inserted before the 3′UTR of endogenous Cyp1a1. An IRES2 sequence separates the reporter genes from the Cyp1a1 C-terminal and a T2A sequence separates the two reporter genes. (c) Representative bioluminescent image of Cyp1a1-nnLuz_v3 adult mice 5 h post-intraperitoneal (IP) injection with 3-mC. IP injection of fungal luciferin at concentrations of 0, 0.015, 0.05, and 0.15 mg/g show dose-dependent luminescence. (d) Quantification of (c). Graph shows mean average radiance of whole mice (n = 3) ± SEM. A one-way ANOVA compares vehicle with luciferin-injected animals with Dunnett’s multiple comparison test. ** p < 0.01. (e) The same animals from (c) imaged using a Sony Alpha 1 camera with SEL50F12GM lens, ISO 800 and exposure of 300 secs. (f) Heart, liver, and lung tissues dissected from Cyp1a1-nnLuz_v3 mice 1 h after fungal luciferin injection. Relative Cyp1a1 and Cyp1b1 mRNA levels as a measure of AHR activation. Cyp1a1 and Cyp1b1 mRNA levels were normalised to housekeeping gene Tbp and are shown relative to vehicle-treated control. Bars show mean (n = 3) ± SEM with a two-way ANOVA to compare vehicle- to luciferin-treated samples and Dunnett’s test to correct for multiple comparisons. ns = not significant.

The aryl hydrocarbon receptor (AHR) is a soluble transcription factor that recognises numerous endogenous and environmental ligands, adjusting cellular physiology to maintain tissue homeostasis [12]. Activation of one of its downstream effectors, the cytochrome P450 protein Cyp1a1, provides a reliable measure of AHR activity [13,14]. The pathway is dynamic and reversible, making it an ideal system to test novel reporter systems, therefore, we developed Cyp1a1-nnLuz_v3 mice where nnLuz_v3 was targeted to the 3′UTR of endogenous Cyp1a1. Here, we compared Cyp1a1-nnLuz_v3 mice with a previously described Cyp1a1-Fluc reporter mouse line [15] and found comparable luminescence intensity and signal distribution. We examined the emission spectrum and substrate kinetics of the two luciferase/luciferin pairs and found that the in vivo emission of nnLuz_v3 could be visualised on consumer-grade cameras. These results derisk the use of the nnLuz_v3 in vivo, suggesting that the fungal luciferase can be used as a molecular reporter in warm-blooded animals, encouraging further optimisation of the fungal luciferin biosynthesis pathway for use in mammalian cells.

2. Results

To determine whether nnLuz_v3 is suitable for in vivo bioluminescence imaging at physiologically relevant levels, we generated an nnLuz_v3 reporter of endogenous AHR activity. The nnLuz_v3 gene and the far-red fluorescent protein iRFP670 (included to validate entry of transgenes) were inserted into the 3′UTR of endogenous Cyp1a1 in the mouse genome. Reporter genes were driven by IRES2 and separated by a T2A site (Figure 1b); therefore, distinct Cyp1a1, iRFP670 and nnLuz_v3 polypeptides were generated from a single RNA transcript, whilst the function of the targeted Cyp1a1 allele was expected to be unaffected. Integration of IRES2-nnLuz_v3-T2A-iRFP670 cassette into mESCs resulted in multiple knock-in clones that luminesced upon treatment with the AHR ligand 6-formylindolo [3,2-β]carbazole (FICZ) (clones A4 and C12 are shown as examples in Supplementary Figure S1a, luminescence signal in blue/green, quantified in b). Clone A4 was used to generate transgenic mice. Transgenic animals appeared to develop normally and showed no apparent phenotypic differences compared to wild-type controls. Pre-treatment with long-acting AHR agonist 3-methylcholanthrene (3-mC) led to development of robust luminescence signal, with brightness dependent on concentration of intraperitoneally (IP) injected luciferin (Figure 1c, quantified in d). Encouragingly, brightness was sufficient for imaging on consumer-grade cameras with 50-megapixel resolution (Figure 1e). Within an hour of fungal luciferin injection, animals displayed no visible phenotypic changes and, reassuringly, no change in tissue mRNA levels of AHR response genes Cyp1a1 or Cyp1b1, suggesting the luciferin did not activate or repress canonical AHR signalling (Figure 1f). The slight, non-significant increase in expression of AHR response genes at 0.15 mg/g in the lungs suggests that this concentration of luciferin should be used as the upper limit for future experiments. From these experiments we cannot discount delayed AHR activation or toxicity associated with repeated luciferin exposure; therefore, these would need to be determined before the Cyp1a1-nnLuz_v3 animals are used in longitudinal studies.

Previously, we described the generation of a similar reporter line, where the firefly luciferase (Fluc) gene is inserted into the 3′UTR of endogenous Cyp1a1, separated from the targeted allele by a T2A site [15]. This model (Cyp1a1-Fluc) provides an opportunity to compare the two luciferase/luciferin systems. Following IP injection of the luciferin substrates, Fluc luminescence peaks 15 min post-injection then deteriorates, whilst nnLuz_v3 luminescence is slower to peak but remains stronger for longer (Figure 2a). Indeed, half-life analysis of these curves suggests that while D-Luc has a t1/2 of 30.7 min, the t1/2 for fungal luciferin is almost 2 h (116.8 min). This likely demonstrates differences between the uptake and retention of the two substrates. When the total radiance emitted across the 90 min period is compared, Fluc and nnLuz_v3 show comparable levels (Figure 2b). Therefore, whilst we cannot make a direct comparison between the two luciferases due to the distinct properties of the two substrates, the comparable radiance levels suggest that nnLuz_v3 is suitable for use as an endogenous reporter in vivo. Moreover, ex vivo imaging of tissues from Cyp1a1-nnLuz_v3 animals show strong luminescence emitted from the lungs, liver and intestine following 3-mC exposure (Figure 2c), corresponding to equivalent luminescence and mRNA results obtained previously in Cyp1a1-Fluc mice [15].

Figure 2.

Figure 2

Comparison between nnLuz_v3 and Fluc as in vivo reporters of AHR activity. (a) Quantification of luminescence emitted from Cyp1a1-nnLuz_v3 (teal) and Cyp1a1-Fluc (black) mice imaged repeatedly across a 90 min time period following IP injection with 0.15 mg/g fungal luciferin or D-luciferin, respectively. Mice were IP injected with 3-mC 5 h prior to the start of imaging. Graph shows mean whole-body radiance (n = 3) for each time point ± SEM. (b) Total radiance emitted by each genotype across the period shown in (a). Graph shows mean (n = 3) ±SEM. (c) Representative bioluminescence images of tissues dissected from Cyp1a1-nnLuz_v3 mice 30 min after IP injection of 0.15 mg/g fungal luciferin. (d,e) Cyp1a1-nnLuz_v3 (nnLuz_v3) and Cyp1a1-Fluc (Fluc) adult mice were IP injected with 0.15 mg/g fungal luciferin or D-luciferin, respectively, and imaged using 20 nm bandpass emission filters across a 500–700 nm range. Mice were IP injected with vehicle or 3-mC 5 h prior to luciferin exposure; for each genotype and emission filter, representative images of vehicle- and 3-mC-treated mice are shown in (d) and quantification of whole-body radiance in (e). For each wavelength, whole-body radiance is normalised against corresponding open-filter value. Graph shows mean (n = 3) ± SEM. (f). Tissues were dissected from Cyp1a1-nnLuz_v3 mice after IP injection with fungal luciferin. Bioluminescence imaging was performed using 20 nm bandpass emission filters across a 500–700 nm range. Graphs show quantification of average radiance (n = 3) ± SEM.

Fluc emits red light in vivo [16], with the peak of emission around 620 nm in Cyp1a1-Fluc mice (Figure 2d, lower panels, and quantified in e, black line). Interestingly, whilst bioluminescence from nnLuz peaks at 520 nm in fungi, in Cyp1a1-nnLuz_v3 mice, luminescence peaked at 520 nm but had an additional, smaller peak at ~620 nm (Figure 2d, upper panels, and quantified in e, teal line). Ex vivo analysis of luminescence of different Cyp1a1-nnLuz_v3 organs showed that most tissues emitted green light, with the exception of the lungs, which exhibited the 520/620 nm double-peaked spectrum (Figure 2f). We detected a similar result in a previously characterised green click beetle luciferase-expressing mouse line [17] (Supplementary Figure S2a), whilst all Cyp1a1-Fluc tissues exhibited a single peak of emission (Supplementary Figure S2b). This suggests that the double-peaked spectrum is not specific to the chemistry of fungal bioluminescence nor related to the expression of Cyp1a1 but is likely an artefact of green-emitting luciferase enzymes. This could be attributed to absorption of green light by haemoglobin, which is known to interfere with the spectrum of green-emitting luciferase enzymes in vivo and is most highly abundant in the lung [18,19].

We next investigated whether fungal luciferin is orally bioavailable, a feature that could enable minimally invasive experiments with animals expressing nnLuz_v3. Mice fed fungal luciferin by oral gavage showed abdominal luminescence signal from as early as 8 min post-ingestion (Supplementary Figure S3a). However, the signal detected following the oral delivery of luciferin differed both in intensity and distribution from that of IP delivery. Following oral gavage, luminescence was primarily detected in the intestines, with very low signal detected in the lungs, heart or liver (Supplementary Figure S3b,c), likely due to luciferin retention in the digestive tract. While short-term exposure to fungal luciferin does not appear to be toxic nor activate canonical AHR signalling, it is unknown whether this accumulation of luciferin would be deleterious to the gut epithelium. This highlights the potential benefits of an autoluminescent model where the luciferin substrate is produced constitutively, and the luciferase enzyme is used as a reporter gene. Here, direct physiological information could be obtained through simple, cheap and non-invasive experiments. Towards this, we began preliminary work optimising the fungal luciferin biosynthesis pathway to function in mammalian cells. We found that, in vitro, HEK293T cells provided the brightest bioluminescence signal; therefore, these were used as a model for these experiments. Measurable bioluminescence was detected from HEK293T cells transfected with all members of the fungal luciferin biosynthesis pathway (Supplementary Figure S3d–f; note that in these experiments, we used a slightly brighter version of the luciferase, nnLuz_v4 [10]). However, luminescence was still ~1000 fold lower compared to cells with exogenously added luciferin and at a level not compatible with in vivo imaging. Indeed, addition of all pathway intermediates (caffeic acid, hispidin, oxyluciferin) (Supplementary Figure S3d) significantly increased the signal (Supplementary Figure S3e). This suggests the pathway can be further optimised in mammalian cells, with gene dosage experiments indicating that hispidin synthase (HispS) is the limiting step (Supplementary Figure S3f).

3. Discussion

Initially discovered as a key player in the xenobiotic response [20], AHR has since been found to respond to a vast array of environmental, dietary and microbial stimuli [12,21]. In the absence of a ligand, the receptor is sequestered in the cytosol as part of a multiprotein complex. Upon ligand binding, AHR dissociates from this complex and translocates to the nucleus where it dimerises with AHR nuclear translocator (ARNT) and activates the expression of target genes [12,21]. Among these target genes is Ahrr, encoding the Aryl hydrocarbon receptor repressor, which targets nuclear AHR for degradation [12]. This is one of a number of ways AHR activity is dynamically regulated [21]. The AHR pathway has been associated with numerous diseases, with AHR inhibitors already in clinical trials for solid tumours [12,22,23]. Therefore, models that non-invasively report on AHR activity have potential for therapeutic development. Previously, we described the generation of an in vivo reporter of AHR activity, where Fluc was inserted into the endogenous Cyp1a1 gene [15]. Here, we developed a Cyp1a1 reporter mouse using the novel luciferase nnLuz_v3. While both models non-invasively report on AHR activity, Cyp1a1-nnLuz_v3 animals have three potential advantages over Cyp1a1-Fluc mice for therapeutic development: 1) the peak of luminescence emitted following IP injection is much broader using the fungal system than the Fluc reporter, potentially allowing quick changes in AHR activity to be visualised in real time; 2) due to the distinct green-shifted emission spectrum and/or the distinct substrate requirements of nnLuz_v3, Cyp1a1-nnLuz_v3 mice can be crossed with other bioluminescent models to examine tumour growth, infiltrates of specific cell types or expression of other genes, in tandem with AHR activity; and 3) following the optimisation of the luciferin biosynthesis pathway, Cyp1a1-nnLuz_v3 mice have the potential to be adapted to become autoluminescent reporters of AHR activity.

In an animal model where a luciferase enzyme is used as a molecular reporter and the luciferin substrate is produced constitutively, obtaining real-time physiological information could be as simple as taking a photo in the dark. Current bioluminescent models (reviewed in [3,4]) would become less invasive, and the potential to split the pathway across cells or species could be harnessed to investigate host–microbe interactions (exemplified in Supplementary Figure S4). The Neonothopanus nambi bioluminescence pathway could be the best tool to generate such a mouse. There has been significant progress in adapting this pathway to produce autoluminescent plants and, unlike the bacterial system [24], there is no toxicity associated with pathway intermediates. However, progress in mammalian models was hindered by the temperature sensitivity of the luciferase enzyme [6]. Here, we showed that a thermostable variant of the fungal luciferase nnLuz could be used as a sensitive and reliable molecular reporter in vitro, in vivo and ex vivo, producing signal strong enough to be visualised on consumer grade cameras. Encouragingly, in mammalian cells, the transgenic expression of all members of the fungal bioluminescence pathway resulted in measurable luminescence. However, radiance was very low and not compatible with the high signal required for in vivo imaging. Therefore, the pathway needs to be further optimised before progression to in vivo models. Our results suggest that hispidin synthase is the rate-limiting step, and therefore boosting HispS expression is essential. This could be achieved by expressing HispS under the control of a strong constitutive promoter or incorporating multiple copies of HispS controlled by different promoters, an approach that could be fortified by diversifying the coding sequences of these HispS copies or using HispS orthologues from other fungal species.

In conclusion, we described a novel tool for visualising AHR activity whilst validating the use of the fungal luciferase nnLuz_v3 for in vivo imaging in warm-blooded animals, providing a promising and important step towards generating mammalian models with self-sustained fungal bioluminescence. Cyp1a1-nnLuz_v3 mice were healthy, showing a strong bioluminescence signal upon AHR activation. The distribution and intensity of luminescence were comparable between Cyp1a1-nnLuz_v3 mice and previously described Cyp1a1-Fluc animals [25], with the fungal luciferase offering some distinct advantages over Fluc that could be exploited for future AHR research.

4. Methods

4.1. Animal Maintenance

Mice were housed in a pathogen-free facility under the following conditions: 21 ± 2 °C; 45–65% humidity; 12 h light–dark cycle with RM3 diet and water ad libidum. Tissues, wood blocks, and tunnels were used to enrich the environment. All animal procedures were performed under a UK Home Office Project Licence and Personal Licences in accordance with the British Home Office Animal (Scientific Procedures) Act 1986 and approved by the Imperial College ethics committee (AWERB: Animal Welfare and Ethical Review Body). Mice were housed and experiments performed at Imperial College, which holds a UK Home Office Establishment Licence (X32FDCFC1), first approved 28.04.87.

4.2. Mammalian Cell Culture and Treatment

ES-E14TG2a (E14) mESC line (ATCC No.: CRL-1821) was used for gene targeting experiments to generate knock-in mESCs clones. mESCs were cultured on a layer of mitotically inactivated mouse embryonic fibroblasts on 0.1% gelatin-coated dishes with KnockOut Dulbecco’s Modified Eagle’s Medium (Gibco, Thermo Fisher Scientific, Loughborough, UK), supplemented with 15% foetal bovine serum (Gibco), 0.5% penicillin–streptomycin (Gibco), 0.1 mM non-essential amino acids (Gibco), 2 mM L-glutamine (Gibco), 0.1 mM 2-mercaptoetanol (Sigma, St. Louis, MO, USA) and 103 U/ml of leukaemia inhibitory factor (ESGRO, Millipore, Watford, UK). Cells were incubated at 37 °C with 5% CO2 and split every 2–3 days. Plasmid DNA transfections on mESCs were performed using Lipofectamine 2000 (Invitrogen, Paisley, UK) and Opti-MEM (Gibco), with cells in suspension in medium without penicillin–streptomycin, following manufacturer instructions. mESCs were treated with 10 nM FICZ (BML-GR206-0100, Enzo, Exeter, UK) or DMSO (Sigma) as vehicle control.

4.3. Cloning, CRISPR and Generation of Cyp1a1-nnLuz_v3 mESCs and Mouse Lines

The nnLuz_v3 gene sequence was provided by Light Bio and codon-optimised for expression in mammalian cells. Gene targeting of nnLuz_v3-T2A-iRFP670 reporter into mouse Cyp1a1 gene was performed using CRISPR in mESCs E14 with an sgRNA sequence (5′- TCTTCAGGCTTAGACTGTCC -3′) specific to cleave DNA 4 nucleotides downstream of the stop codon located in exon 7. The sgRNA sequence and its corresponding antisense complementary sequence were ordered as DNA oligos (Sigma) and cloned using BbsI restriction enzyme (Thermo Fisher Scientific, Loughborough, UK) into the Cas9-GFP-containing plasmid pX458. pSpCas9(BB)-2A-GFP (pX458) was a gift from Feng Zhang (Addgene plasmid # 48138; chttp://n2t.net/addgene:48138, URL (accessed on 20 October 2026).; RRID: Addgene_48138) [26]. To induce reporter knock-in integration by DNA repair through homologous recombination, a donor DNA template containing 1 Kb of each homology arm was generated and used as a targeting vector. We also included a modified version of the internal ribosomal entry site sequence (IRES2) between the stop codon of Cyp1a1 and the start codon of nnLuz_v3 to allow independent protein synthesis of the reporter nnLuz_v3-T2A-iRFP670 polypeptide from the endogenous Cyp1a1 protein. In addition, a neomycin resistance cassette (NeoR) flanked by loxP sites was included in the donor DNA template for selection of mESC clones. Each component of the targeting vector was generated by PCR from existing DNA plasmids or, in the case of the homology arms, from genomic DNA from E14 mESCs. After purification, PCR fragments were cloned into the targeting vector through Gibson assembly method using a NEBuilder HiFi DNA Assembly Cloning Kit (E5520S, NEB, Hitchin, UK) according to manufacturer instructions. CRISPR was performed on E14 mESCs by co-transfecting both pX458 and targeting control plasmids using Lipofectamine 2000 (Invitrogen), followed by FACS enrichment of GFP-positive cells 24 h post-transfection. GFP-positive mESCs were seeded at very low density in 10 cm plates containing a layer of mitotically inactivated mouse embryonic fibroblasts on 0.1% gelatin-coated dishes. After 1 week, mESC colonies were manually picked under the microscope and individually expanded in the presence of neomycin (150 μg/ml). Individual clones were screened by PCR and selected based on phenotypic similarities to parental non-transfected E14 mESCs, such as growth rate and cell morphology. Karyotype was examined on selected clones prior to microinjection into blastocysts for mouse line generation. Primers used for Cyp1a1-nnLuz mESCs and mice genotyping are outlined in Table 1.

Table 1.

Primer and oligo sequences. F, forward; R, reverse; RevCom, reverse complement. Underlined sequences indicate BbsI site used for cloning and transcription of sgRNA in pX458 vector. UTR, untranslated region.

Assay Purpose Target Sequence (5′ to 3′)
qPCR Genotyping nnLuz_v3 (F) CTGATCGACAAAGTGATCCC
qPCR Genotyping nnLuz_v3 (R) CTGGGGATGTTCAGAGGG
qPCR Genotyping iRFP670 (F) AGGTCGATCTCACCTCCTGC
qPCR Genotyping iRFP670 (R) CCGGCATTTTCCGTAATGC
qPCR Genotyping Cyp1a1 (F) CTGTGAACACTTCCAAGTGC
qPCR Genotyping Cyp1a1 (R) TGTGCCCAGTGTGTGTTCAG
qPCR Genotyping NeoR (F) TGATTGACAAGACCGGCTTCC
qPCR Genotyping NeoR (R) CTGTCATCTCACCTTGCTCC
RT-qPCR Gene Expression Cyp1a1 (F) CCTGTCCTCCGTTACCTGCC
RT-qPCR Gene Expression Cyp1a1 (R) AGGCTGTCTGTGATGTCCCG
RT-qPCR Gene Expression Cyp1b1 (F) CCACCAGCCTTAGTGCAGAC
RT-qPCR Gene Expression Cyp1b1 (R) GGCCAGGACGGAGAAGAGT
RT-qPCR Gene Expression Tbp (F) GAAGAACAATCCAGACTAGCAGCA
RT-qPCR Gene Expression Tbp (R) CCTTATAGGGAACTTCACATCACAG
CRISPR Gene targeting Cyp1a1 3′ UTR CACCGTCTTCAGGCTTAGACTGTCC
CRISPR Gene targeting Cyp1a1 3′ UTR (RevCom) AAACGGACAGTCTAAGCCTGAAGAC

4.4. Other Animal Lines

Cyp1a1-Fluc mice were generated by OzGene (Bentley DC, Australia). A firefly luciferase (Fluc) gene was inserted into endogenous Cyp1a1, separated from the C-terminal region by a T2A sequence (see [15] for details).

4.5. In Vivo Experiments

For all in vivo experiments involving Cyp1a1-Fluc or Cyp1a1-nnLuz_v3 animals, adult (6- to 12-week-old) mice were first weighed and intraperitoneal (IP) injected with 3-mC (213942, Sigma) dissolved in corn oil (Sigma) at 26.5 mg/kg. Corn oil was used as a vehicle control. Where possible, cage-mate siblings were used for test and vehicle measurements to minimise potential confounders. No animals had been subject to any additional procedures. Animals were chosen at random for 3-mC or vehicle injection; however, blinding was not performed to ensure consistency in the layout of the bioluminescence images produced (with control mice at the side of the image). Criteria dictated a priori stated that animals be excluded from experiments if in visible poor health (abnormal weight, activity or coat condition) at onset or should health deteriorate following 3-mC injection. No animals were excluded from the experiments or analysis.

4.6. Bioluminescence Imaging

All bioluminescence imaging was performed using IVIS Spectrum (Perkin Elmer, High Wycombe, UK) and Living Image software (version 4.3.1), using a stage temperature of 37 °C.

Fungal luciferin was synthetised as described in [27]. For imaging experiments, luciferin was dissolved in DMSO to a concentration of 200 mg/ml, then diluted in dH2O to working concentrations on the day of use. D-luciferin (Perkin Elmer) was dissolved and stored in dH2O.

For bioluminescence imaging of mESCs, fungal luciferin was diluted in mESC medium to achieve a final concentration of 650 µg/ml. Cells were imaged with IVIS two minutes after exposure to fungal luciferin using field of view C, binning 4 and depth 0.5 for a total of 5 minutes.

For in vivo bioluminescent imaging experiments, Cyp1a1-Fluc or Cyp1a1-nnLuz_v3 adult mice were IP injected with 3-mC 5 h (IP) or ~14 h (oral gavage) before luciferin exposure. Mice were IP injected with 0.15 mg/g D-luciferin (Cyp1a1-Fluc) or 0.15 mg/g fungal luciferin (Cyp1a1-nnLuz). For oral gavage, Cyp1a1-nnLuz_v3 adult mice were fed 0.15 mg/g fungal luciferin. Mice were anesthetised by isoflurane inhalation and imaged using IVIS Spectrum within 10–15 min of luciferin exposure. When assessing the kinetics of luminescence emitted from Cyp1a1-Fluc and Cyp1a1-nnLuz_v3 mice, consecutive images were taken across a 90–120 min period, and the animals remained anesthetised throughout. Half-life values were calculated using the formula t1/2 = 0.693/ Kel, where Kel is the absolute value of the SLOPE with y values converted to natural log.

Adult mice were IVIS imaged using 30 s exposure, field of view C or D, binning 1 and depth 1.5. In the majority of cases, the ‘open’ filter was used, capturing all emitted light. For generation of emission spectra, consecutive images were taken on IVIS Spectrum using emission filters with wavelengths ranging from 500 to 700 nm with 20 nm bandpass.

4.7. RNA Extraction and RT-qPCR

RNA was extracted using an RNeasy Mini Kit (Qiagen, Manchester, UK). Tissue samples were lysed in RLT buffer with a 5 mm stainless steel bead (Qiagen) using a TissueLyser II (Qiagen) for 4 min at 24,000 rpm. To digest fibrous tissue, heart samples were incubated with 10 μg/ml Proteinase K at 55 °C for 1 h. Next, to remove debris, all tissue samples were centrifuged at top speed for 3 min and the supernatant retained. Total RNA was purified from the supernatant using an RNeasy Mini Kit according to the manufacturer’s instructions, including the on-column DNase digestion step using an On-column RNase-Free DNase Set (Qiagen).

RT-qPCR was performed using QuantiTect SYBR Green PCR mix (Qiagen) in a CFX thermocycler (Bio-Rad, Hemel Hempstead, UK) with 0.4 μM primers (sequences in Table 1). The amplification protocol consisted of 40 cycles of 94 °C for 15 s and 60 °C for 30 s. For each set of primers, efficiency was calculated using the formula E  =  10 − 1/Slope. Relative RNA levels were then determined using the formula EIcontrol Ct-sample Ct/EHcontrol Ct-sample Ct, where EI  =  efficiency of primers of interest, and EH  =  efficiency of the housekeeping primer set, Tbp.

4.8. Autonomous Bioluminescence in HEK293T Cells

4.8.1. Exogenous Substrate Addition

HEK293T cells (ATCC No.: CRL-3216) were seeded into Sarstedt Lumox 96-well plates at appr. 10,000 cells per well in DMEM (PanEco, Moscow, Russia) cultural medium supplemented with 10% FBS. Then, 24 h after seeding, cells were transfected with plasmid mixture (Table 2) by PolyFect (Qiagen) transfection reagent (1.5 µL per well); 24 h after transfection, growth medium was removed, and PBS with or without luminescence pathway substrate was added (all at 100 µM). The luminescent signal was registered by Tecan Spark plate reader during 30 min (48 time frames), 1 s per well exposure.

Table 2.

Autonomous bioluminescence HEK293T cell plasmid mixture.

Plasmid Link Amount per Well
pCMV - HpaC - 3′UTR_SV40 https://benchling.com/s/seq-y8xzpxq9TLLVO5Ixpga1 25 ng
pCMV - HpaB - 3′UTR_SV40 https://benchling.com/s/seq-xHOdW4VfdL5RKY8f1afX 25 ng
pCMV - RcTAL - 3′UTR_SV40 https://benchling.com/s/seq-EALzCyyBM2CVLEHFTzuG 25 ng
pCMV - nnLuz_v4 - tSV40 https://benchling.com/s/seq-43dTNxDtZPOiOh2OKyKe 25 ng
pCMV - nnH3H_v2 - tSV40 https://benchling.com/s/seq-CtGTqXBypyVV6gkO1rrj 25 ng
pCMV - nnCPH - tSV40 https://benchling.com/s/seq-d56KUa9vSH2fBpYT4aSF 25 ng
pCMV - SFP - tSV40 https://benchling.com/s/seq-aK15X8T4vDqR5R090gov 25 ng
pCMV - mcitHispS - tSV40 https://benchling.com/s/seq-yiQg45S3X9Lzxv0oQHSz 50 ng

URLs accessed on 20 October 2026.

4.8.2. Gene Titration

HEK293T cells were seeded into Sarstedt Lumox 96-well plates at appr. 10’000 cells per well in DMEM (PanEco) cultural medium supplemented with 10% FBS. Then, 24 h after seeding≤ cells were transfected with plasmid mixture (Table 3) by PolyFect (Qiagen) transfection reagent (1 µL per well); 24 h after transfection, growth medium was removed, and PBS with 100 µM of caffeic acid was added. The luminescent signal was registered immediately by Tecan Spark plate reader during 20 min (33 time frames for decreasing gene titration and 41 time frames for increasing gene titration), 1 s per well exposure.

Table 3.

Gene titration plasmid mixture.

Plasmid Link Amount per Well
pCMV - nnLuz_v4 - tSV40 https://benchling.com/s/seq-43dTNxDtZPOiOh2OKyKe 25 ng (2.5 ng in low nnLuz)
pCMV - nnH3H_v2 - tSV40 https://benchling.com/s/seq-CtGTqXBypyVV6gkO1rrj 25 ng (2.5 ng in low H3H)
pCMV - nnCPH - tSV40 https://benchling.com/s/seq-d56KUa9vSH2fBpYT4aSF 25 ng
pCMV - SFP - tSV40 https://benchling.com/s/seq-aK15X8T4vDqR5R090gov 25 ng (2.5 ng in low SFP)
pCMV - mcitHispS - tSV40 https://benchling.com/s/seq-yiQg45S3X9Lzxv0oQHSz 50 ng (5 ng in low HispS)

URLs accessed on 20 October 2026.

4.9. Statistics and Reproducibility

Microsoft Excel was used for calculations, and GraphPad Prism (version 10) was used to create graphs and for statistical analysis. Graphs show the mean of experimental replicates, with error bars showing standard error (SEM). Multi-group comparisons were tested using ANOVAs with Dunnett’s or Šidàk’s multiple comparison tests. Specific details of each test are provided in the figure legends.

Supplementary Materials

The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/ijms27219586/s1. Refs. [17,25] are cited in Supplementary Material.

ijms-27-09586-s001.zip (924.9KB, zip)

Author Contributions

N.V., K.S.S. and A.G.F. conceptualised this study. The majority of experiments were performed by H.J.G. and N.V. with help from A.S., F.G. and N.M.M. assembled plasmids and performed experiments in HEK293T cells. A.A.F. synthesised fungal luciferin for experiments in this project. Mouse imaging support was provided by A.S. and mouse transgenics and husbandry support was provided by Z.W. and M.M., H.J.G. and K.S.S. wrote the manuscript, with input from all co-authors. All authors have read and agreed to the published version of the manuscript.

Institutional Review Board Statement

All animal procedures were performed under a UK Home Office Project License and Personal Licenses in accordance with the British Home Office Animal (Scientific Procedures) Act 1986 and approved by the Imperial College AWERB committee. (Approval No. X32FDCFC1; approval date: 28 April 1987).

Informed Consent Statement

Not applicable.

Data Availability Statement

All numerical source data are provided in Supplementary Data File S1.

Conflicts of Interest

Karen S. Sarkisyan is a shareholder of Light Bio, Inc. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.” which can be found here.

Funding Statement

This work was funded by the Medical Research Council (MRC) (A.G.F. by MC_PC_23024 and MC_UP_1605/12, K.S by UKRI MC-A658-5QEA0). KSS was supported by UKRI Biotechnology and Biological Sciences Research Council through the International Science Partnerships Fund (grant number APP33664). Some of the cell culture experiments were supported by RSF, project number 24-74-10105. Luciferin synthesis was funded by RSF project number 25-76-30006. N.V received an ERDA award from the Institute of Clinical Sciences, Imperial College London.

Footnotes

Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

References

  • 1.Prescher J.A., Contag C.H. Guided by the light: Visualizing biomolecular processes in living animals with bioluminescence. Curr. Opin. Chem. Biol. 2010;14:80–89. doi: 10.1016/j.cbpa.2009.11.001. [DOI] [PubMed] [Google Scholar]
  • 2.Kaskova Z.M., Tsarkova A.S., Yampolsky I.V. 1001 lights: Luciferins, luciferases, their mechanisms of action and applications in chemical analysis, biology and medicine. Chem. Soc. Rev. 2016;45:6048–6077. doi: 10.1039/c6cs00296j. [DOI] [PubMed] [Google Scholar]
  • 3.Gleneadie H.J., Dimond A., Fisher A.G. Harnessing bioluminescence for drug discovery and epigenetic research. Front. Drug Discov. 2023;3:1249507. doi: 10.3389/fddsv.2023.1249507. [DOI] [Google Scholar]
  • 4.Dimond A., Van de Pette M., Fisher A.G. Illuminating Epigenetics and Inheritance in the Immune System with Bioluminescence. Trends Immunol. 2020;41:994–1005. doi: 10.1016/j.it.2020.09.001. [DOI] [PubMed] [Google Scholar]
  • 5.Brodl E., Winkler A., Macheroux P. Molecular Mechanisms of Bacterial Bioluminescence. Comput. Struct. Biotechnol. J. 2018;16:551–564. doi: 10.1016/j.csbj.2018.11.003. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Kotlobay A.A., Sarkisyan K.S., Mokrushina Y.A., Marcet-Houben M., Serebrovskaya E.O., Markina N.M., Somermeyer L.G., Gorokhovatsky A.Y., Vvedensky A., Purtov K.V., et al. Genetically encodable bioluminescent system from fungi. Proc. Natl. Acad. Sci. USA. 2018;115:12728–12732. doi: 10.1073/pnas.1803615115. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Kiszka K.A., Dullin C., Steffens H., Koenen T., Rothermel E., Alves F., Gregor C. Autonomous bioluminescence emission from transgenic mice. Sci. Adv. 2025;11:eads0463. doi: 10.1126/sciadv.ads0463. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Brinker T., Gunther A., Kiszka K.A., Rhee J.S., Gregor C. Labeling and imaging of neurons with a genetically encoded autonomous bioluminescence system. Sci. Rep. 2026;16:12892. doi: 10.1038/s41598-026-46211-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Khakhar A., Starker C.G., Chamness J.C., Lee N., Stokke S., Wang C., Swanson R., Rizvi F., Imaizumi T., Voytas D.F. Building customizable auto-luminescent luciferase-based reporters in plants. Elife. 2020;9:e52786. doi: 10.7554/eLife.52786. Correction in Elife 2020, 9, e60938. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Shakhova E.S., Karataeva T.A., Markina N.M., Mitiouchkina T., Palkina K.A., Perfilov M.M., Wood M.G., Hoang T.T., Hall M.P., Fakhranurova L.I., et al. An improved pathway for autonomous bioluminescence imaging in eukaryotes. Nat. Methods. 2024;21:406–410. doi: 10.1038/s41592-023-02152-y. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Mitiouchkina T., Mishin A.S., Somermeyer L.G., Markina N.M., Chepurnyh T.V., Guglya E.B., Karataeva T.A., Palkina K.A., Shakhova E.S., Fakhranurova L.I., et al. Plants with genetically encoded autoluminescence. Nat. Biotechnol. 2020;38:944–946. doi: 10.1038/s41587-020-0500-9. Erratum in Nat Biotechnol. 2020, 38, 1001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Rothhammer V., Quintana F.J. The aryl hydrocarbon receptor: An environmental sensor integrating immune responses in health and disease. Nat. Rev. Immunol. 2019;19:184–197. doi: 10.1038/s41577-019-0125-8. [DOI] [PubMed] [Google Scholar]
  • 13.Wei Y.D., Bergander L., Rannug U., Rannug A. Regulation of CYP1A1 transcription via the metabolism of the tryptophan-derived 6-formylindolo[3,2-b]carbazole. Arch. Biochem. Biophys. 2000;383:99–107. doi: 10.1006/abbi.2000.2037. [DOI] [PubMed] [Google Scholar]
  • 14.Wei Y.D., Helleberg H., Rannug U., Rannug A. Rapid and transient induction of CYP1A1 gene expression in human cells by the tryptophan photoproduct 6-formylindolo[3,2-b]carbazole. Chem. Biol. Interact. 1998;110:39–55. doi: 10.1016/s0009-2797(97)00111-7. [DOI] [PubMed] [Google Scholar]
  • 15.Veland N., Gleneadie H.J., Brown K.E., Sardini A., Pombo J., Dimond A., Burns V., Sarkisyan K., Schiering C., Webster Z., et al. Bioluminescence imaging of Cyp1a1-luciferase reporter mice demonstrates prolonged activation of the aryl hydrocarbon receptor in the lung. Commun. Biol. 2024;7:442. doi: 10.1038/s42003-024-06089-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Luker K.E., Luker G.D. Applications of bioluminescence imaging to antiviral research and therapy: Multiple luciferase enzymes and quantitation. Antivir. Res. 2008;78:179–187. doi: 10.1016/j.antiviral.2008.01.158. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Gleneadie H.J., Fernandez-Ruiz B., Sardini A., Van de Pette M., Dimond A., Prinjha R.K., McGinty J., French P.M.W., Bagci H., Merkenschlager M., et al. Endogenous bioluminescent reporters reveal a sustained increase in utrophin gene expression upon EZH2 and ERK1/2 inhibition. Commun. Biol. 2023;6:318. doi: 10.1038/s42003-023-04666-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Zhao H., Doyle T.C., Coquoz O., Kalish F., Rice B.W., Contag C.H. Emission spectra of bioluminescent reporters and interaction with mammalian tissue determine the sensitivity of detection in vivo. J. BioMed Opt. 2005;10:41210. doi: 10.1117/1.2032388. [DOI] [PubMed] [Google Scholar]
  • 19.Mezzanotte L., Que I., Kaijzel E., Branchini B., Roda A., Lowik C. Sensitive dual color in vivo bioluminescence imaging using a new red codon optimized firefly luciferase and a green click beetle luciferase. PLoS ONE. 2011;6:e19277. doi: 10.1371/journal.pone.0019277. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Poland A., Glover E., Kende A.S. Stereospecific, high affinity binding of 2,3,7,8-tetrachlorodibenzo-p-dioxin by hepatic cytosol. Evidence that the binding species is receptor for induction of aryl hydrocarbon hydroxylase. J. Biol. Chem. 1976;251:4936–4946. doi: 10.1016/s0021-9258(17)33205-2. [DOI] [PubMed] [Google Scholar]
  • 21.Sondermann N.C., Fassbender S., Hartung F., Hatala A.M., Rolfes K.M., Vogel C.F.A., Haarmann-Stemmann T. Functions of the aryl hydrocarbon receptor (AHR) beyond the canonical AHR/ARNT signaling pathway. Biochem. Pharmacol. 2023;208:115371. doi: 10.1016/j.bcp.2022.115371. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Narasimhan S., Stanford Zulick E., Novikov O., Parks A.J., Schlezinger J.J., Wang Z., Laroche F., Feng H., Mulas F., Monti S., et al. Towards Resolving the Pro- and Anti-Tumor Effects of the Aryl Hydrocarbon Receptor. Int. J. Mol. Sci. 2018;19:1388. doi: 10.3390/ijms19051388. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Bayer A. First-in-Humans Dose Finding Study for an Aryl Hydrocarbon Receptor Inhibitor (AhRi) in Patients With Advanced Cancer. ClinicalTrials. gov identifier: NCT04069026. Updated August 4. 2022. [(accessed on 20 October 2026)]; Available online: https://clinicaltrials.gov/study/NCT04069026.
  • 24.Hollis R.P., Lagido C., Pettitt J., Porter A.J., Killham K., Paton G.I., Glover L.A. Toxicity of the bacterial luciferase substrate, n-decyl aldehyde, to Saccharomyces cerevisiae and Caenorhabditis elegans. FEBS Lett. 2001;506:140–142. doi: 10.1016/s0014-5793(01)02905-2. [DOI] [PubMed] [Google Scholar]
  • 25.Van de Pette M., Dimond A., Galvao A.M., Millership S.J., To W., Prodani C., McNamara G., Bruno L., Sardini A., Webster Z., et al. Epigenetic changes induced by in utero dietary challenge result in phenotypic variability in successive generations of mice. Nat. Commun. 2022;13:2464. doi: 10.1038/s41467-022-30022-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Ran F.A., Hsu P.D., Wright J., Agarwala V., Scott D.A., Zhang F. Genome engineering using the CRISPR-Cas9 system. Nat. Protoc. 2013;8:2281–2308. doi: 10.1038/nprot.2013.143. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Bubyrev A.I., Tsarkova A.S., Kaskova Z.M. Optimization of Fungal Luciferin Synthesis. Russ. J. Bioorg. Chem. 2019;45:183–185. doi: 10.1134/S106816201902002x. [DOI] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

ijms-27-09586-s001.zip (924.9KB, zip)

Data Availability Statement

All numerical source data are provided in Supplementary Data File S1.


Articles from International Journal of Molecular Sciences are provided here courtesy of Multidisciplinary Digital Publishing Institute (MDPI)

RESOURCES